Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K3 | P46734 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 11/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13578142 | 0.94 | MAP2K3 (0.60) | MAP2K3CNR2RORCRAD51HTR4 | |
| Trifluoroacetic Acid SCHEMBL4320381 | 0.90 | CNR2 (0.51) | MAP2K3CNR2RORCPPARGHTR4 | |
| Trifluoroacetic Acid SCHEMBL4341502 | 0.85 | CNR2 (0.48) | CNR2RORCPPARG | |
| SCHEMBL13578002 | 0.85 | CNR2 (0.53) | MAP2K3CNR2RORCPPARGHTR4 | |
| Trifluoroacetic Acid SCHEMBL4327394 | 0.84 | MAP2K3 (0.54) | MAP2K3CNR2RORCPPARGRAD51 | |
| Trifluoroacetic Acid SCHEMBL4341766 | 0.83 | CNR2 (0.55) | CNR2RORCPPARGHTR4 | |
| Trifluoroacetic Acid SCHEMBL4321534 | 0.82 | MAP2K3 (0.51) | MAP2K3RORCPPARGHTR4 | |
| Trifluoroacetic Acid SCHEMBL4339626 | 0.82 | MAP2K3 (0.53) | MAP2K3RORCPPARGRAD51HTR4 | |
| Trifluoroacetic Acid SCHEMBL4325308 | 0.81 | CNR2 (0.53) | MAP2K3CNR2RORCPPARGRAD51 | |
| Trifluoroacetic Acid SCHEMBL4325507 | 0.81 | MAP2K3 (0.50) | MAP2K3CNR2RORCHTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | MAP2K3 1970/4885CNR2 1/4885RORC 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.